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Abstract
Background: The purpose of this study was to test the hypothesis that estradiol (E2) level on day 3 may be associated
with in vitro fertilization (IVF) outcomes.
Methods: The records of patients who received clomiphene citrate 100 mg/day plus human menopausal
gonadotropin 150 IU/day from day 3 and received frozen-thawed embryo transfers were reviewed. Patients
were divided into three groups: group A (E2 ≤30 pg/ml), group B (30< E2 ≤50 pg/ml), and group C (E2 >50 pg/ml).
A total of 1080 cycles from 941 patients were included.
Results: The number of eggs and MII oocytes were less in group C than group A (both, P = 0.001). The embryo
implantation (P = 0.006) and clinical pregnancy rates (P = 0.036) were lower in group C than group B, and the rates
were similar between group A and B.
Conclusion: Maintaining the serum E2 level from 30 to 50 pg/ml may result in a higher clinical pregnancy rate in
IVF cycles.
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Introduction
Ovarian stimulation is an integral part of in vitro
fertilization (IVF), and multiple oocytes are usually re-
trieved during a successful IVF cycle [1]. In recent years
there has been an increasing trend towards using milder
ovarian stimulation protocols to decrease the risk of
ovarian hyperstimulation syndrome (OHSS) [2, 3]. In
addition to decreasing the risk of OHSS, milder stimula-
tion protocols can significantly decrease the physical and
psychological stress of patients, increase patient conveni-
ence, reduce treatment costs, and reduce the risk of
aneuploidy in human preimplantation embryos [4, 5].
Clomiphene citrate (CC) has been used for over 40 years
as the primary drug for ovarian stimulation during IVF,
and is the drug of choice for first line treatment of
anovulatory dysfunction stemming from a variety of
causes [6–8]. It is orally administered, has few side effects,
is easily available, and is inexpensive [9]. In recent years
the use of CC has increased because of the increased use
of mild and mini ovarian stimulation protocols [10, 11].
As is well-known, CC is a competitive inhibitor of estra-
diol (E2) and can block the negative feedback of E2 by
binding to estrogen receptors at the hypothalamic level,
thus increasing the endogenous secretion of follicle stimu-
lating hormone (FSH) [12]. CC is normally used from
cycle day 3 onward. Ovarian function varies in the
menstrual cycle, and in both long and short stimulation
protocols E2 is routinely measured before the initiation of
ovulation. For patients with a poor ovarian reserve, FSH
should be measured before ovulation, and there is a rela-
tionship between FSH and E2: FSH decreases as E2
increases, and E2 is more stable than FSH. Thus, E2 may
reflect ovarian function. The E2 level on cycle day 3 varies
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widely among patients, but it is not known if the E2 level
on cycle day 3 has an effect on the outcomes after CC
ovarian stimulation. Some studies, however, have suggested
that E2 level early in the cycle is associated with IVF
outcomes. An early study by Phelps et al. [13] found that
an E2 level on day 4>75 pg/ml was associated with higher
clinical pregnancy and delivery rates than a level ≤75 pg/
ml. Similarly, Prasad et al. [14] reported that a higher E2
level on day 2 and on the day of trigger was associated with
a higher pregnancy rate in women undergoing IVF.
Thus, the purpose of this study was to determine if E2
level on cycle day 3 is associated with IVF outcomes in
women receiving CC ovarian stimulation. The findings
may help to determine the optimal E2 level at which to
initiate CC.
Materials and methods
Study subjects and protocol
The records of patients who underwent a CC plus hu-
man menopausal gonadotropin (hMG) protocol at the
Shanghai Ji’ai Genetics and IVF Institute between October
2012 and September 2013 were retrospectively reviewed.
Inclusion criteria for the study were: 1) Poor ovarian re-
sponse after prior stimulation with a long or short proto-
col, and the number of collected oocytes was no higher
than 3; or 2) Baseline FSH was greater than 10 IU/ml at
the initiation of first ovulation. Exclusion criteria were: 1)
Polycystic ovary syndrome (PCOS); 2) Prior ovarian re-
sponse was adequate; 3) Ovarian cysts; 4) Endometriosis.
This study was approved by the Institutional Review
Board of the Shanghai Ji’ai Genetics and IVF Institute, and
because of the retrospective nature the requirement of
informed patient consent was waived.
Ovarian stimulation was carried out using CC (Clomi-
phene Citrate Tablets, Codal Synto Ltd., Limassol, Cyprus)
in combination with hMG (Menotrophins for Injection,
Lizhu Pharmaceutical, China). Per protocol, CC 100 mg/
day was administrated orally as an extended regimen from
cycle day 3 until induction of oocyte maturation, and
hMG (150 IU/day) was administered during the same
period. Monitoring included ultrasonography and meas-
urement of serum concentrations of E2, progesterone, and
luteinizing hormone (LH), and was usually begun on
day 9 and continued every day or every other day ac-
cording to the development of follicles. Maturation was
triggered by administration of nafarelin acetate (Synarel,
Pfizsurge, USA) 200 mg, a gonadotropin-releasing hor-
mone agonist (GnRHa), when the diameter of the domin-
ant follicle had reached 18 mm or more. Nafarelin was
used as the trigger because nafarelin is convenient to use
and patients can inject it themselves. In addition, when
CC is used there is no pituitary down-regulation. Thus,
nafarelin may induce an endogenous LH peak to pro-
mote the maturation of follicles. Oocytes were then
retrieved after 34–35 h. After oocyte retrieval, IVF were
performed according to sperm quality.
Embryo development was observed on day 3 after IVF.
Good quality for day 3 embryos was defined as grades 1
and 2 according to Scott’s criteria [15]. Embryos with six
cells or more were cryopreserved using vitrification as
previously described [16, 17]. Briefly, vitrification was per-
formed in 7.5 % dimethyl sulfoxide (DMSO)/7.5 % ethyl-
ene glycol (EG) for 2–3 min followed by incubation in
15 % DMSO/15 % EG for 45 s prior to loading on the
vitrification carrier. The cryoprotectant was removed dur-
ing warming by sequential washes in 0.25 M and 0.125 M
sucrose in culture medium.
Natural or hormone replacement cycles were used
according to the patient’s menstruation. Endometrial
thickness and shape were observed by ultrasound from
cycle day 10. All patients underwent frozen-thawed em-
bryo transfer (FET) when the endometrial thickness
reached 8 mm, and a total of 1–3 embryos were trans-
ferred per cycle. Luteal phase support was provided with
progesterone 40 mg/d by intramuscular injection and
dydrogesterone (Citicoline Sodium and Glucose Injection,
Solvay Pharmaceutical) 20 mg/d orally. Beta-human chori-
onic gonadotropin (β-hCG) concentration was measured
on day 14 after embryo transfer. Implantation was con-
sidered to have occurred when the β-hCG concentra-
tion was >200 mIU/ml. Ultrasound was performed
2 weeks later, and clinical pregnancy was defined as the
presence of a fetal heartbeat.
Statistical analysis
Continuous variables were expressed as median (IQR;
interquartile range, range between the 25th and 75th per-
centile) due to skewed distributions, and the Kruskal-
Wallis test was carried out to test differences among
patients with the three E2 levels. Mann–Whitney U test
was performed for post-hoc analysis of continuous data
if any significance was revealed by the Kruskal-Wallis
test. Categorical data were expressed as count (percent-
age), and tested by chi-square test. In order to control
for the effects of age, body mass index (BMI), and E2
level at baseline, analysis of covariance (ANCOVA),
Poisson regression, and logistic regression were imple-
mented for continuous variables, count data (i.e., success-
ful fertilization and successful cleavage), and cancelled
cycles, respectively. Due to the assumptions of the
parametric method, rank transformation was applied to
scale outcomes with skewed distributions (e.g., FSH
during ovulation stimulation and duration of stimula-
tion) before multivariable analysis. A value of P < 0.05
was considered to indicate statistical significance. If
post-hoc testing was necessary, Bonferroni correction
was performed and the significance level was adjusted
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to 0.017 (0.05/3). All analyses were performed with
IBM SPSS statistical software for Windows (Version
22.0. IBM Corp., Armonk, NY, USA).
Results
Study population
A total of 1080 cycles of 941 patients were included in this
study. Data were classified into three groups according to
E2 level measured on day 3 during ovulation stimula-
tion: group A (E2 ≤30 pg/ml, 316 cycles), group B (30<
E2 ≤50 pg/ml, 451 cycles), and group C (E2 >50 pg/ml,
313 cycles). As shown in Table 1, the three groups were
similar with respect to duration of infertility, ovarian
stimulation cycles, number of embryos transferred, and
baseline FSH level. However, patients in group C were
older than those in group A (P = 0.015), and had a lower
BMI than patients in the other two groups (P = 0.010
compared with group A; P = 0.004 compared with group
B). The baseline E2 level of patients in group A was signifi-
cantly lower than that in group B and C (both, P < 0.001).
Ovarian stimulation and fertilization
FSH level during ovulation stimulation, E2 level on HCG
day, number of embryos, and good embryos were similar
across the three groups. The fertilization rate, cleavage
rate, and percentage of patients with canceled cycles were
also similar (Table 2). However, the duration of stimula-
tion, gonadotropin level, and the number of eggs and ma-
ture oocytes (MII) were different among the three groups.
Compared with group A, the duration of stimulation was
shorter and the amount of gonadotropin used was less in
group B (both, P ≤ 0.004) and C (both, P ≤ 0.001), and the
duration of stimulation was shortest in group C (P = 0.001
compared with group B). The number of eggs and MII
oocytes were also less in group C than group A (both,
P = 0.001) (Table 2). Results of the multivariable ana-
lysis were consistent, except for the comparison of FSH
during ovulation stimulation; although a significant dif-
ference of FSH between the three groups was revealed
by ANCOVA, no pair-wise differences were found after
Bonferroni correction.
FET results
Except for the embryo implantation rate and ongoing
clinical pregnancy rate, FET outcomes were similar
between the groups (Table 3). Although patients in
group B seemed to have the highest implantation and
clinical pregnancy rates, only the differences between
group B and group C reached statistical significance;
higher probabilities of embryo implantation (P = 0.023)
and ongoing pregnancy (P = 0.036) were seen in group B
as compared with group C.
Discussion
The results of this study showed that patients with a
lower E2 level on day 3 required a greater amount of
gonadotropin and longer duration of stimulation, though
other measures were similar between the groups. Most
importantly, the embryo implantation and clinical preg-
nancy rates in group B (30< E2 ≤50 pg/ml) were higher
than in group C (E2 >50 pg/ml), and similar to that in
group A (E2 ≤30 pg/ml).
In this study there are a number of reasons for the clas-
sification of E2 level, and for examining E2 level on day 3.
Estrogen has a normal distribution, and an estrogen of
30–50 pg/ml is found in about 90 % of subjects. We have
also clinically observed that 50 pg/ml is an upper limit of
normal for E2. Furthermore, at our hospital a chemilumin-
escence method was used to detect the blood estrogen,
and the value of 30 pg/ml is the lower limit of detection of
chemiluminescent methods (values <30 pg/ml may not
be measured precisely). With respect to classifying E2
on day 3, first available studies focus on E2 on the day
of HCG use, or several days after Gn administration,
Table 1 Baseline characteristics of the three study groups
Group A: Group B: Group C: P
E2≤ 30 pg/ml 30 < E2≤ 50 pg/ml E2 > 50 pg/ml
Number of cycles 316 451 313
Age, years 34 (31, 38) 35 (31, 39) 35 (31, 40)* 0.049
Body mass index, kg/m2 21.2 (19.9, 23.3) 21.4 (20, 23.1) 20.8 (19.5, 22.2)* ** 0.008
Duration of infertility, years 5 (3, 9) 5 (3, 8) 5 (3, 8) 0.809
Number of past ovarian stimulation cycles 2 (1, 3) 2 (1, 3) 2 (1, 2) 0.487
Number of past embryo transfers 2 (1, 3) 2 (1, 2) 1 (1, 2) 0.146
Baseline FSH, IU/L 8.6 (7.1, 10.7) 8.7 (7.1, 11.1) 8.9 (7.3, 11.8) 0.353
Baseline E2, pg/mL 33 (24, 45) 38.5 (29, 50.5)* 48 (33, 62)* ** <0.001
Data are presented as median (interquartile range), and examined by Kruskal-Wallis test
FSH follicle-stimulating hormone
*Indicates significant difference between group A and given group, P < 0.017
**Indicates significant difference between group B and group C, P < 0.017
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and no studies have been conducted to investigate the
relationship between E2 before Gn therapy and outcomes.
Second, CC + hMG was administered since day 3 of the
menstrual cycle when FSH and E2 are routinely measured
to evaluate ovarian function and guide Gn therapy. In
clinical practice, we found that E2 was related to FSH and
the central feedback of E2 could directly affect FSH and
then influence the response to ovulation, which is usually
neglected. Most investigators have focused on FSH. Third,
during ovulation E2 may be used to reflect the ovarian
response. However, E2 before therapy may also reflect the
ovarian reserve, and early detection of E2 may be helpful
Table 2 Serum E2 levels and ovarian stimulation and fertilization outcomes
Group A: Group B: Group C: P Padj
e
E2 ≤30 pg/ml 30< E2 ≤50 pg/ml E2 >50 pg/ml
Number of cycles 316 451 313
FSH during ovulation stimulation, IU/La 9.5 (7.5, 11.8) 8.9 (7.5, 10.6) 9 (7.7, 11) 0.098 0.047
Duration of stimulation, daysa 9 (8, 10) 8 (7, 10)* 8 (7, 9)* ** <0.001 <0.001
Gonadotropin, ampules 16 (12.5, 18) 14 (10, 18)* 14 (10.8, 17.5)* <0.001 <0.001
E2 at HCG day, pg/ml
a 2216 (1391, 3319) 2150.5 (1406, 3294) 2179.5 (1337.5, 3223) 0.991 0.976
Number of eggsa 6 (3, 9) 5 (3, 8) 5 (2, 7)* 0.004 0.031
Number of mature oocytes (MII)a 5 (3, 8) 4 (2, 7) 4 (2, 6)* 0.003 0.032
Number of embryosa 2 (1, 4) 2 (1, 4) 2 (1, 4) 0.340 0.771
Number of good quality embryosa 2 (1, 4) 2 (1, 3) 2 (1, 3) 0.440 0.638
Successful fertilizationb,c 1470 (82.7) 1968 (84.2) 1261 (82.9) 0.375 0.756
Successful cleavageb,d 1432 (97.4) 1917 (97.4) 1217 (96.5) 0.257 0.995
Cancelled cyclesb 46 (14.6) 55 (12.2) 52 (16.6) 0.221 0.290 (Group B),
0.766 (Group C)
E2 estradiol, HCG human chorionic gonadotropin
Continuous data are presented as median (interquartile range), and examined by Kruskal-Wallisa test. Categorical data are expressed as n (%) and tested by
Chi-squareb test
cFertilization rate was calculated as: total number of fertilized oocytes/total number of mature oocytes
dCleavage rate was calculated as: total number of cleaved oocytes/total number of fertilized oocytes
eRank transformation was applied to continuous data, and tested by analysis of covariance adjusting for age, body mass index (BMI), and baseline E2 level.
Successful fertilization and cleavage rate were tested by Poisson regression adjusting for age, BMI, and baseline E2 level. Probability of cancelled cycle was
examined by logistic regression adjusting for age, BMI, and baseline E2 level
*Indicates significant difference between group A and given group, P < 0.017
*Indicates significant difference between group B and group C, P < 0.017
Table 3 Serum E2 levels and frozen embryo transfer (FET) outcomes
Group A: Group B: Group C: P Padj
d
E2 ≤ 30 pg/ml 30 < E2≤ 50 pg/ml E2 > 50 pg/ml
Number of transfer cycles 241 350 225
Number of transferred embryosa 2 (2, 3) 2 (2, 3) 2 (2, 3) 0.574 0.510
Number of transferred good quality embryosa 2 (1, 2) 2 (1, 2) 2 (1, 2) 0.366 0.431
Endometrial thickness, mma 10 (9, 11) 10 (9, 11) 10 (9, 11) 0.543 0.383
Successful embryo implantationb,c 115 (22.0) 195 (25.1) 93 (18.6)* 0.023 -
Ongoing clinical pregnancyb 94 (29.9) 154 (34.1) 78 (25.1)* 0.027 0.552 (Group A)
0.036 (Group B)
Abortionb 9 (2.8) 18 (4) 16 (5.1) 0.349 0.198 (Group A)
0.520 (Group B)
Ectopic pregnancyb 3 (0.9) 6 (1.3) 1 (0.3) 0.357 0.410 (Group A)
0.213 (Group B)
Dash indicates statistical analysis with adjustment was unavailable as there were second-hand data used for analysis
Continuous data are presented as median (interquartile range) and examined by Kruskal-Wallisa test. Categorical data are expressed as n (%) and tested by
chi-square testb
cEmbryo implantation rate was calculated as: total number of embryos which are implanted/total number of embryos transferred
dRank transformation was applied to continuous data, and tested by analysis of covariance adjusting for age, body mass index (BMI), and baseline E2 level.
Probabilities of ongoing clinical pregnancy, abortion, and ectopic pregnancy were examined by logistic regression adjusting for age, BMI, and baseline E2 level
*Indicates significant difference between group B and group C, P < 0.017; chi-square test with Bonferroni correction
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to guide clinical therapy. E2 is an important hormone of
the hypothalamic-pituitary-ovarian axis, and positive feed-
back of E2 in the luteal phase may induce FSH release and
recruitment of follicles.
One of the major challenges of assisted reproduction
technologies (ART) is developing effective approaches to
obtain good quality embryos for transfer. Thus, improving
the stimulation protocol is an important area of IVF re-
search. CC is now wildly used in mini and mild ovarian
stimulation protocols, and provides advantages over other
medications [2, 18, 19]. Clomiphene compounds include
enclomiphene and zuclomiphene. Enclomiphene may
affect the hypothalamus as an estrogen antagonist, and
thus blocks both the negative and positive feedback of
estrogen, and the result of these effects is alterations in
GnRH pulsatility. Zucolmiphene may weakly affect the
pituitary as an estrogen agonist, and it can slightly in-
crease the sensitivity of the pituitary gland to GnRH [2].
The overall effect of clomiphene compounds is to trigger
the release of both FSH and LH from the anterior pituit-
ary. FSH stimulates the development of follicles, which
then release E2. Once serum E2 reaches a critical level, it
triggers the release of LH and ovulation. GnRH agonists
and antagonists have been used to prevent this, but in
recent years it has been noted that the administration of
CC until the day before HCG with prevent the premature
LH surge [2, 19]. This is because enclomiphene acts as an
estrogen antagonist at the level of the hypothalamus, and
not only blocks the negative feedback of E2, but also its
positive feedback resulting in blockage of the LH surge
[20]. Although the premature LH surge is blocked by CC,
the LH level is adequate for the development of follicles to
the late phase, and this method provides better results
than an agonist and antagonist [21]. Interestingly, Ye et al.
[22] found that luteal E2 pre-treatment before a GnRH an-
tagonist protocol significantly increased the serum LH
level and rate of premature LH surge, but had no signifi-
cant effect on implantation, clinical pregnancy, live birth,
and early pregnancy loss rates as compared with a long
GnRH agonist protocol.
FSH level is typically tested at the beginning of stimula-
tion [23, 24], and the importance of E2 level is frequently
overlooked. However, a number of studies have examined
the effect of E2 level and IVF outcomes. Phelps et al. [13]
examined patients undergoing IVF with luteal phase leu-
prolide acetate and found that an E2 level on day 4>75 pg/
ml was associated with clinical pregnancy and delivery
rates of 42 and 32 %, respectively, which were significantly
higher than rates of 9 and 6.8 %, respectively, when the
day 4 E2 level was ≤75 pg/ml. Prasad et al. [14] reported
that E2 levels on day 2 and on the day of trigger in
women undergoing IVF were higher in those that
became pregnant than those that did not become preg-
nant (31.9 ± 12.6 pg/ml and 1996.46 ± 1252.36 pg/ml vs.
27.6 ± 12.3 pg/ml and 1525.1 ± 1116.42 pg/ml, respect-
ively). DiMattina et al. [25] examined patients undergo-
ing natural cycle IVF and found that when the E2 level
on the day of hCG was <101 pg/ml no clinical pregnan-
cies occurred.
In a study of 2995 consecutive IVF cycles in 1889
patients with non-donor oocyte retrieval and FET, Imudia
et al. [26] found that serum E2 above the 90
th percentile
on the day of hCG administration was associated with a
significantly lower fertilization rate as compared with
patients with a serum E2 below the 90
th percentile (68.6 ±
20 % vs. 71.6 ± 21 %, P = 0.02); but the E2 level did not
impact embryo development, implantation, or clinical preg-
nancy and spontaneous miscarriage rates. Kondapalli et al.
[27] examined 1712 IVF cycles, and reported that a >10 %
decrease in E2 level after hCG administration was associ-
ated with 40–50 % reduction in the clinical pregnancy and
live birth rates, and a post-hCG E2 plateau ± 10 % lowered
the clinical pregnancy and live birth rates by >25 %.
The standard initial ovarian stimulation protocol used at
our center consists of luteal phase GnRHa down-regulation
followed by administration of exogenous gonadotropins.
This method has been guided by the increased number of
oocytes and greater pregnancy rate obtained with this com-
bination, as well as the benefits of better scheduling and
lower cancellation rates due to premature LH surges fol-
lowing pituitary desensitization [28]. However, patients who
fail or respond poorly to standard controlled ovarian stimu-
lation protocols often continue to respond poorly in subse-
quent cycles. Current evidence suggests that increasing the
dose of exogenous gonadotropins is of limited value for
these patients [29]. In patients with a poor response to
gonadotropins, Kutlusoy et al. [30] found that the clinical
pregnancy rate was significantly higher in patients that
received luteal phase support of 2 mg E2 plus progesterone
than in those that received progesterone only (37 % vs.
12 %, respectively). Elassar et al. [31] showed that when low
responders received a higher dose of gonadotropins in a
successive cycle, the magnitude and pattern of the ovarian
response remained unchanged. Similarly, van Hooff et al.
[32] reported that doubling the hMG dose in the course of
an IVF cycle is not effective in enhancing ovarian
response. These findings suggest that some patients
appear to respond more favorably to their endogenous
gonadotropins [33].
There are limitations of this study that need to be con-
sidered. First is the retrospective nature of the analysis.
In addition, the study was performed at a single center
and examined the results of a single stimulation proto-
col. Both natural and hormone replacement cycles were
included in the analysis, and the type of cycle may have
an effect on IVF outcomes. Other factors associated with
IVF outcomes such as anti- Müllerian hormone and pro-
gesterone levels were not examined [34, 35]. Lastly, at
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our center the protocol for ovulation induction is deter-
mined according to the ovarian reserve, and not selected
subjectively. The patients in the present study had poor
ovarian reserve or were older, and had poor responses to
ovulation stimulation with other protocols. Thus, the
patients may be considered a group in whom it is diffi-
cult to induce ovulation.
Conclusion
Serum E2 level on day 3 can affect the duration of stimu-
lation and amount of gonadotropins used, and a level of
30–50 pg/ml is associated with a higher clinical preg-
nancy rate than levels above this range.
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